Tonix Pharmaceuticals (NASDAQ:TNXP) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Dawson James began coverage on Tonix Pharmaceuticals in a research report on Wednesday, February 28th. They issued a “buy” rating and a $3.00 price target on the stock.

Tonix Pharmaceuticals Price Performance

NASDAQ TNXP opened at $0.17 on Thursday. The firm has a market cap of $14.77 million, a P/E ratio of -0.02 and a beta of 2.21. The stock’s 50-day moving average is $0.32 and its two-hundred day moving average is $0.42. Tonix Pharmaceuticals has a fifty-two week low of $0.17 and a fifty-two week high of $3.69. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.53 and a quick ratio of 1.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Monday, April 1st. The company reported ($0.86) earnings per share (EPS) for the quarter. The firm had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.95 million. On average, analysts anticipate that Tonix Pharmaceuticals will post -3.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in TNXP. JPMorgan Chase & Co. grew its position in Tonix Pharmaceuticals by 36.9% during the first quarter. JPMorgan Chase & Co. now owns 285,321 shares of the company’s stock worth $66,000 after buying an additional 76,935 shares in the last quarter. Bank of New York Mellon Corp grew its position in Tonix Pharmaceuticals by 18.4% during the first quarter. Bank of New York Mellon Corp now owns 1,321,327 shares of the company’s stock worth $305,000 after buying an additional 205,428 shares in the last quarter. BlackRock Inc. grew its position in Tonix Pharmaceuticals by 12.3% during the first quarter. BlackRock Inc. now owns 34,392,362 shares of the company’s stock worth $7,916,000 after buying an additional 3,760,804 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Tonix Pharmaceuticals by 14.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,248,831 shares of the company’s stock worth $288,000 after buying an additional 161,099 shares in the last quarter. Finally, Northern Trust Corp grew its position in Tonix Pharmaceuticals by 7.8% during the first quarter. Northern Trust Corp now owns 4,139,924 shares of the company’s stock worth $952,000 after buying an additional 300,199 shares in the last quarter. 82.26% of the stock is owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.